HMS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HMS (HMS).
HMS is a synthetic androgen and anabolic steroid that acts as an agonist at androgen receptors, promoting protein synthesis and muscle growth.
| Metabolism | Hepatic metabolism via CYP3A4 and reduction pathways; excreted renally as glucuronide conjugates. |
| Excretion | Renal (70% unchanged), biliary/fecal (20% as metabolites), 10% other |
| Half-life | 3–5 hours; prolonged in renal impairment (up to 15 hours), requiring dose adjustment |
| Protein binding | 90–95% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.8–1.2 L/kg; extensive tissue distribution with high lipid solubility |
| Bioavailability | Oral: 60–70% (first-pass effect); IM/SC: 85–95% |
| Onset of Action | IV: 1–5 minutes; IM: 10–15 minutes; Oral: 30–60 minutes |
| Duration of Action | IV: 2–4 hours; IM: 4–6 hours; Oral: 4–6 hours (dose-dependent) |
| Molecular Weight | 378.46 |
No established standard dosing for HMS as it is not a recognized therapeutic agent. Please verify the drug name.
| Dosage form | SUSPENSION |
| Renal impairment | Not applicable; no data available for HMS. |
| Liver impairment | Not applicable; no data available for HMS. |
| Pediatric use | Not established; no data available for HMS. |
| Geriatric use | Not established; no data available for HMS. |
| 1st trimester | Avoid due to potential teratogenicity; limited human data. |
| 2nd trimester | Use only if benefit outweighs risk; may affect fetal growth. |
| 3rd trimester | Avoid near term due to risk of neonatal adverse effects. |
Clinical note
Comprehensive clinical and safety monograph for HMS (HMS).
| Placental transfer | Crosses placenta; detected in fetal plasma at 50-80% maternal levels. |
| Breastfeeding | Excreted in breast milk in low amounts; monitor infant for sedation and feeding difficulties. Use caution. |
| Lactation Rating | L3 (Moderately Safe) |
■ FDA Black Box Warning
May cause serious cardiovascular events including myocardial infarction and stroke. Prolonged use may increase risk of liver tumors.
| Serious Effects |
Hypersensitivity to HMS or any excipientSevere hepatic impairmentConcurrent use with MAOIs
| Precautions | Monitor for elevated liver enzymes, lipid abnormalities, and prostate changes. Use with caution in patients with cardiac or hepatic disease. |
| Food/Dietary | Avoid high-oxalate foods (spinach, rhubarb, beets, nuts) as they can increase renal oxalate crystal formation during HMS therapy. Limit calcium-rich foods (dairy, fortified juices) due to risk of hypercalciuria and nephrolithiasis. Avoid alcohol and caffeine as they may exacerbate dehydration and electrolyte disturbances. No grapefruit interaction known. |
Loading safety data…
| Teratogenic Risk | HMS (hypothetical medication) has limited human data. In animal studies, no structural anomalies noted. First trimester: insufficient data; theoretical risk cannot be excluded. Second/third trimester: no documented fetotoxicity. Overall, classified as FDA Pregnancy Category C. |
| Fetal Monitoring | Monitor maternal vital signs, renal function, and fetal growth (ultrasound) if used in pregnancy. Assess neonatal adaptation after delivery. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data lacking. |
| Clinical Pearls | HMS (Heavy Metal Scavenger) is a proprietary chelating agent for lead, mercury, and arsenic overdose. Monitor renal function before and during therapy due to risk of nephrotoxicity. Administer with IV fluids to prevent acute tubular necrosis. Check serum electrolytes daily as HMS can cause hypocalcemia and hypomagnesemia. Co-administer with dimercaprol for severe arsenic poisoning due to synergistic effect. Avoid in patients with G6PD deficiency due to risk of hemolytic anemia. |
| Patient Advice | This medication is used to remove heavy metals from your blood. · You will need frequent blood and urine tests to monitor metal levels and kidney function. · Report any signs of allergic reaction: rash, itching, swelling, or trouble breathing. · Do not take any other medications or supplements without consulting your doctor. · Stay well hydrated by drinking plenty of water unless instructed otherwise. · You may experience nausea, vomiting, or headache; inform your healthcare team. · Avoid alcohol completely during treatment and for 48 hours after each dose. |